Nitsch RM - Search Results

1

Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Cattepoel S, et al. Among authors: nitsch rm. PLoS One. 2011 Apr 5;6(4):e18296. doi: 10.1371/journal.pone.0018296. PLoS One. 2011. PMID: 21483675 Free PMC article.

2

From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease.

Nitsch RM. Nitsch RM. Neurodegeneration. 1996 Dec;5(4):477-82. doi: 10.1006/neur.1996.0066. Neurodegeneration. 1996. PMID: 9117566 Review.

3

The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.

Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. Nitsch RM, et al. Ann Neurol. 2000 Dec;48(6):913-8. Ann Neurol. 2000. PMID: 11117548

4

Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease.

Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH, Nitsch RM. Hock C, et al. Among authors: nitsch rm. Ann N Y Acad Sci. 2000;920:285-91. doi: 10.1111/j.1749-6632.2000.tb06937.x. Ann N Y Acad Sci. 2000. PMID: 11193166 Clinical Trial.

5

Increased cystatin C in astrocytes of transgenic mice expressing the K670N-M671L mutation of the amyloid precursor protein and deposition in brain amyloid plaques.

Steinhoff T, Moritz E, Wollmer MA, Mohajeri MH, Kins S, Nitsch RM. Steinhoff T, et al. Among authors: nitsch rm. Neurobiol Dis. 2001 Aug;8(4):647-54. doi: 10.1006/nbdi.2001.0412. Neurobiol Dis. 2001. PMID: 11493029

6

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.

Götz J, Chen F, van Dorpe J, Nitsch RM. Götz J, et al. Among authors: nitsch rm. Science. 2001 Aug 24;293(5534):1491-5. doi: 10.1126/science.1062097. Science. 2001. PMID: 11520988

7

Genetics of interleukin 6: implications for Alzheimer's disease.

Papassotiropoulos A, Hock C, Nitsch RM. Papassotiropoulos A, et al. Among authors: nitsch rm. Neurobiol Aging. 2001 Nov-Dec;22(6):863-71. doi: 10.1016/s0197-4580(01)00294-9. Neurobiol Aging. 2001. PMID: 11754993 Review.

8

Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation.

Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM. Mohajeri MH, et al. Among authors: nitsch rm. J Biol Chem. 2002 Sep 6;277(36):33012-7. doi: 10.1074/jbc.M203193200. Epub 2002 Jun 14. J Biol Chem. 2002. PMID: 12068009 Free article.

9

Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo.

Mohajeri MH, Wollmer MA, Nitsch RM. Mohajeri MH, et al. Among authors: nitsch rm. J Biol Chem. 2002 Sep 20;277(38):35460-5. doi: 10.1074/jbc.M202899200. Epub 2002 Jul 8. J Biol Chem. 2002. PMID: 12105192 Free article.

10

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Hock C, et al. Among authors: nitsch rm. Nat Med. 2002 Nov;8(11):1270-5. doi: 10.1038/nm783. Epub 2002 Oct 15. Nat Med. 2002. PMID: 12379846 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters